BioLineRx Company Profile (NASDAQ:BLRX)

About BioLineRx

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications.

Industry, Sector and Symbol:

• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Exchange: NASDAQ
• Symbol: BLRX
• CUSIP:

Key Metrics:

• Previous Close: $1.23
• 50 Day Moving Average: $0.94
• 200 Day Moving Average: $0.92
• 52-Week Range: $0.71 - $1.73
• Trailing P/E Ratio: N/A
• Foreward P/E Ratio: -3.87
• P/E Growth: 0.00
• Market Cap: $67.71M
• Outstanding Shares: 56,423,000
• Beta: 1.63

Profitability:

• Return on Equity: -28.52%
• Return on Assets: -26.52%

Debt:

• Debt-to-Equity Ratio: 0.01%
• Current Ratio: 15.25%
• Quick Ratio: 15.25%

Additional Links:

• Visit BioLineRx's Official Website
• View BLRX on Google Finance
• View BLRX on Yahoo Finance
• View BLRX's Company Profile on Reuters
• Search for BioLineRx Ltd. on Google

Companies Related to BioLineRx:

• Vascular Biogenics (NASDAQ:VBLT)
• Derma Sciences (NASDAQ:DSCI)
• Second Sight Medical Products (NASDAQ:EYES)
• Corium International (NASDAQ:CORI)
• Synta Pharmaceuticals Corp. (NASDAQ:MDGL)
• VolitionRX Ltd (NYSEMKT:VNRX)
• OncoCyte Corp. (NYSEMKT:OCX)
• VBI Vaccines, Inc. - (NASDAQ:VBIV)
• Endocyte (NASDAQ:ECYT)
• Corindus Vascular Robotics (NYSEMKT:CVRS)

Earnings

Earnings History for BioLineRx (NASDAQ:BLRX)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call	Details
8/11/2016	Q216	($0.07)	($0.09)			View	Listen
5/17/2016	Q116	($0.08)	($0.10)			View	Listen
3/10/2016	Q415	($0.06)	($0.07)			View	Listen
11/16/2015	Q315	($0.08)	($0.03)			View	Listen
8/20/2015	Q215	($0.10)	($0.09)			View	Listen
5/18/2015	Q115	($0.10)	($0.08)			View	Listen
11/10/2014	Q314	($0.17)	($0.01)			View	N/A
8/6/2014	Q214	($0.09)	($0.12)			View	N/A
5/20/2014	Q114	($0.11)	($0.01)			View	N/A
3/17/2014		($0.15)	($0.20)			View	N/A
11/13/2013		($0.18)	($0.20)			View	N/A
8/6/2013	Q213		($0.02)			View	N/A
5/7/2013		($0.02)	($0.20)			View	N/A
11/14/2012	Q312		($0.15)			View	N/A

(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BioLineRx (NASDAQ:BLRX)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	1	($0.08)	($0.08)	($0.08)
Q2 2016	1	($0.07)	($0.07)	($0.07)
Q3 2016	1	($0.07)	($0.07)	($0.07)
Q4 2016	1	($0.08)	($0.08)	($0.08)

(Data provided by Zacks Investment Research)

Dividends

Dividend History for BioLineRx (NASDAQ:BLRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for BioLineRx (NASDAQ:BLRX)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for BioLineRx (NASDAQ:BLRX)

Date	Headline
	Analysts Set EPS Target of $-0.07 For BioLineRx Ltd. (NASDAQ:BLRX) - Stocks Daily (NASDAQ:BLRX) www.stocksdaily.net - September 26 at 4:02 PM
	FDA Approves AMGN's 1st Biosimilar, MRNS On Track, All Ears For DRRX, PTIE (NASDAQ:BLRX) www.rttnews.com - September 26 at 8:37 AM
	BioLineRx (BLRX) Stock Soars on Liver Drug Licensing Agreement (NASDAQ:BLRX) www.thestreet.com - September 24 at 8:07 AM
	Unusual 11 Mid-Day Movers 9/23: (IMPV) (BLRX) (TWTR) Higher; (ENPH) (APPS) (RAVE) Lower - StreetInsider.com (NASDAQ:BLRX) www.streetinsider.com - September 23 at 3:20 PM
	Shares Recorded Gapping Higher Pre-Market: BioLineRx, Ltd. (NASDAQ:BLRX) - Post News (NASDAQ:BLRX) www.kentuckypostnews.com - September 23 at 3:20 PM
	BioLineRx (BLRX) Enters ESLD in-Licensing Agreement - StreetInsider.com (NASDAQ:BLRX) www.streetinsider.com - September 23 at 3:20 PM
	Company Update (NASDAQ:BLRX): BioLineRx Ltd. Presents Corporate Objectives at Investor Breakfast Meeting in NY - Smarter Analyst (NASDAQ:BLRX) www.smarteranalyst.com - September 23 at 3:20 PM
	Why These 5 Stocks Are Winning Today (NASDAQ:BLRX) www.insidermonkey.com - September 23 at 3:20 PM
	7:01 am BioLineRx announces in-licensing of novel treatment for liver failure conditions; second project in-licensed under strategic collaboration with Novartis (NVS (NASDAQ:BLRX) finance.yahoo.com - September 23 at 8:58 AM
	BioLineRx Announces In-licensing of Novel Treatment for Liver Failure Conditions Under Strategic Collaboration (NASDAQ:BLRX) www.publicnow.com - September 23 at 8:58 AM
	BioLineRx (BLRX) Updates on Corp. Objectives; Plans Ramp-up of Several BL-8040 Combo Phase 1bs (NASDAQ:BLRX) www.streetinsider.com - September 22 at 4:02 PM
	BioLineRx Ltd. Presents Corporate Objectives at Investor Breakfast Meeting in NY (NASDAQ:BLRX) finance.yahoo.com - September 22 at 4:02 PM
	BioLineRx Starts Phase 2a Combo Trial For Pancreatic Cancer (NASDAQ:BLRX) - Post News (NASDAQ:BLRX) www.kentuckypostnews.com - September 21 at 8:25 AM
	BioLineRx (BLRX) Commences BL-8040 Combo Phase 2a in Pancreatic Cancer - StreetInsider.com (NASDAQ:BLRX) www.streetinsider.com - September 21 at 8:25 AM
	Company Update (NASDAQ:BLRX): Bioline RX Ltd Announces Initiation of Phase 2a Trial of BL-8040 in Combination ... - Smarter Analyst (NASDAQ:BLRX) www.smarteranalyst.com - September 20 at 9:45 AM
	BioLineRx Announces Initiation of Phase 2a Trial of BL-8040 in Combination With KEYTRUDA® (pembrolizumab) for Treatment of Pancreatic Cancer (NASDAQ:BLRX) www.publicnow.com - September 20 at 9:45 AM
	Can BioLineRx Ltd. (NASDAQ:BLRX) Hit High Of $7? - Stocks Daily (NASDAQ:BLRX) www.stocksdaily.net - September 13 at 5:31 PM
	BioLineRx Hosts Investor Meeting (NASDAQ:BLRX) investingnews.com - September 9 at 3:49 PM
	BioLineRx (BLRX) Announces Presentation of Positive BL-8040 Phase 2a Data in AML (NASDAQ:BLRX) www.streetinsider.com - September 9 at 3:49 PM
	BioLineRx Ltd. to Host Investor Breakfast ... (NASDAQ:BLRX) ih.advfn.com - September 9 at 3:49 PM
	BioLineRx Ltd. to Host Investor Breakfast Meeting September 22, 2016 in New York - PR Newswire (press release) (NASDAQ:BLRX) www.prnewswire.com - September 9 at 8:46 AM
	BioLineRx Ltd. to Host Investor Breakfast Meeting September 22, 2016 in New York (NASDAQ:BLRX) www.publicnow.com - September 9 at 8:46 AM
	BioLineRx (BLRX) Announces Presentation of Positive BL-8040 Phase 2a Data in AML - StreetInsider.com (NASDAQ:BLRX) www.streetinsider.com - September 8 at 7:58 AM
	BioLineRx Presents Final Results from Phase 2a Trial for Relapsed/Refractory AML at SOHO Conference (NASDAQ:BLRX) finance.yahoo.com - September 8 at 7:58 AM
	BioLineRx Announces Clinical Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab in Multiple Oncol... (NASDAQ:BLRX) ih.advfn.com - September 7 at 8:57 PM
	Placing BioLineRx Ltd. (NASDAQ:BLRX) Shares Under the Microscope - Post News (NASDAQ:BLRX) www.kentuckypostnews.com - September 7 at 3:52 PM
	Shares Gapping Up Before the Open: BioLineRx, Ltd. (NASDAQ:BLRX) - Post News (NASDAQ:BLRX) www.kentuckypostnews.com - September 7 at 12:37 PM
	BioLineRx (BLRX), Genentech Enter Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab - StreetInsider.com (NASDAQ:BLRX) www.streetinsider.com - September 7 at 12:37 PM
	BioLineRx Announces Clinical Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab in Multiple Oncology Indications (NASDAQ:BLRX) www.publicnow.com - September 7 at 12:37 PM
	BioLineRx to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York (NASDAQ:BLRX) www.marketwatch.com - August 29 at 8:37 AM
	BioLineRx (BLRX), I-Bridge Capital Form New JV in China - StreetInsider.com (NASDAQ:BLRX) www.streetinsider.com - August 27 at 8:40 AM
	BioLineRx : and I-Bridge Capital Establish a New Drug Development Joint Venture in China (NASDAQ:BLRX) www.4-traders.com - August 25 at 9:18 PM
	BioLineRx and I-Bridge Capital launch new joint venture (NASDAQ:BLRX) www.pehub.com - August 25 at 3:55 PM
	BioLineRx (BLRX), I-Bridge Capital Form New JV in China (NASDAQ:BLRX) www.streetinsider.com - August 25 at 8:44 AM
	BioLineRx and I-Bridge Capital Establish a New Drug Development Joint Venture in China (NASDAQ:BLRX) www.publicnow.com - August 25 at 8:44 AM
	Can BioLineRx Ltd. (NASDAQ:BLRX) Meet Analysts Expectations? - Stocks Daily (NASDAQ:BLRX) www.stocksdaily.net - August 20 at 3:54 PM
	Will BioLineRx Ltd. (NASDAQ:BLRX) Surprise Analysts This Quarter? - Stocks Daily (NASDAQ:BLRX) www.stocksdaily.net - August 14 at 8:41 AM
	BioLineRx downgraded by Maxim Group (NASDAQ:BLRX) finance.yahoo.com - August 12 at 12:32 PM
	BioLineRx Reports Second Quarter 2016 Financial Results (NASDAQ:BLRX) finance.yahoo.com - August 11 at 12:01 PM
	BioLineRx : Signs Second Clinical Immuno-Oncology Collaboration Agreement to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer (NASDAQ:BLRX) www.4-traders.com - August 8 at 3:56 PM
	BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer (NASDAQ:BLRX) www.publicnow.com - August 8 at 8:41 AM
	BioLineRx to Report Second Quarter Results on August 11, 2016 (NASDAQ:BLRX) www.publicnow.com - August 4 at 12:27 PM
	Novartis AG (NYSE:NVS)’s Partner Bioline RX Announce In-Licensing Of Liver Fibrosis Project (NASDAQ:BLRX) marketexclusive.com - August 3 at 3:54 PM
	News Review - Bioline RX Ltd (NASDAQ:BLRX) - Hot Stocks Point (NASDAQ:BLRX) www.hotstockspoint.com - August 2 at 8:41 AM
	BioLineRX Ltd.: BioLineRx Announces In-licensing of Liver Fibrosis Project Under Strategic Collaboration (NASDAQ:BLRX) www.twst.com - August 1 at 8:46 AM
	BioLineRx Announces In-licensing of Liver Fibrosis Project Under Strategic Collaboration (NASDAQ:BLRX) www.publicnow.com - August 1 at 7:21 AM
	Biolinerx Limited Ads (NASDAQ:BLRX) Short Interest Decreased By 42.65% - Consumer Eagle (NASDAQ:BLRX) www.consumereagle.com - July 16 at 3:49 PM
	Biolinerx Limited Ads (NASDAQ:BLRX) Shorts Decreased by 42.65% After Short Covering - Press Telegraph (NASDAQ:BLRX) presstelegraph.com - July 15 at 2:29 PM
	Analyst Target and Average Rating Watch: BioLineRx Ltd. (NASDAQ:BLRX) - Press Telegraph (NASDAQ:BLRX) presstelegraph.com - July 15 at 2:29 PM
	BioLineRx Ltd. (NASDAQ:BLRX) Wall Street Analyst Recommendation Outlook - Telanagana Press (NASDAQ:BLRX) telanaganapress.com - July 13 at 3:53 PM

Social

BioLineRx (NASDAQ:BLRX) Chart for Wednesday, September, 28, 2016